{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"ceroid-lipofuscinosis-neuronal-4-kufs-type","columns":[{"countQualifier":"Onset group unspecified","gene":"DNAJC5","key":"population-e10385c957f361faffe8","label":"CLN4","mondoId":"MONDO:0008083","onsetQualifier":null,"originColumnKey":"MONDO:0008083","originalViews":[{"key":"MONDO:0008083","label":"CLN4","scopeLabel":"Genetic form","sourceScope":null}],"recordKeys":["084c236607bba227797c1844cef956fc4a7394a4aee5f709fc3bf61776bd99a9","0e398dfeb71117633ac390cdf24bf381712688a97fd9d6137836b2fd2d658d4e","2f2c4dff1498b9881816ae90dfe0a8b7d30b88b293a7c37b7fd9d54df44013ba","40c65404fd20f6274b6ebfad7651c2b7b0465d094b012943adf6d5ab37dfcc1d","4b0e87dd303a42317cae57f63aaef2c6bff3f4bba3c8d9b294bd872802a278bf","5ef8fd4633e0672fcdf93f3be65e761888d0c5cfb15b40a50c8a118a2a0bc374","63aa04dcdbd5940c65cfa6ac59b50cb0550f3716c70b9ebabaffced5825b6ee5","7111795ce66f6eb98ec211996d5116e6ff83e7507f19e344e793513044af079b","82e47ed85797203888ca365222a9acffe00f8fd5baad5c7f1186e59ba71cde1e","8a18de3696c522566e6bfdb3d1668d3cfe6546ae6bb23b4379231e40cfc7bc6f","8f594580ea777b2403e502629f354d4343df6efd6011fd40a42c62549b91dcfa","9936b8282b19d66636d0a823e74439313806e61960f320725dde99ad979d1542","ab85586d56b4ef67f9553a21315dd00d33a6c06b5d967e9a85db2642956ff356","bab6e4ecbc77258986369e47c1b8c0c33d3834a696bc04fa952476b727b8526e","e3f5791da630ebe0712e1778f68fa48c8dd5cc195d1ecfc9ad9afe88d220fc67","ebc0184364a2b557b59d3862155df896c281ca7c70b68d4169269ec14e857210","fc634fce0cdc4b94182201a6d5eb928e2c0c218aec96b6aa387d14711e90847e"],"recordQualifiers":{"4b0e87dd303a42317cae57f63aaef2c6bff3f4bba3c8d9b294bd872802a278bf":"Onset group unspecified","9936b8282b19d66636d0a823e74439313806e61960f320725dde99ad979d1542":"Onset group unspecified","ab85586d56b4ef67f9553a21315dd00d33a6c06b5d967e9a85db2642956ff356":"Onset group unspecified"},"scopeLabel":"Genetic form","sourceIds":["OMIM:162350"],"sourceScope":null}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-e10385c957f361faffe8"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0001317","HP:0002071","HP:0001251","HP:0008765","HP:0002069","HP:0003205","HP:0000726"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":5,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":17,"sourceGroups":{"omim":12,"published":5}},"features":[{"hpoId":"HP:0001317","label":"Abnormal cerebellum morphology","primary":true},{"hpoId":"HP:0002071","label":"Abnormality of extrapyramidal motor function","primary":true},{"hpoId":"HP:0001251","label":"Ataxia","primary":true},{"hpoId":"HP:0008765","label":"Auditory hallucination","primary":true},{"hpoId":"HP:0002069","label":"Bilateral tonic-clonic seizure","primary":true},{"hpoId":"HP:0003205","label":"Curvilinear intracellular accumulation of autofluorescent lipopigment storage material","primary":true},{"hpoId":"HP:0000726","label":"Dementia","primary":true},{"hpoId":"HP:0000716","label":"Depression","primary":false},{"hpoId":"HP:0003208","label":"Fingerprint intracellular accumulation of autofluorescent lipopigment storage material","primary":false},{"hpoId":"HP:0002074","label":"Increased neuronal autofluorescent lipopigment","primary":false},{"hpoId":"HP:0032794","label":"Myoclonic seizure","primary":false},{"hpoId":"HP:0001336","label":"Myoclonus","primary":false},{"hpoId":"HP:0001300","label":"Parkinsonism","primary":false},{"hpoId":"HP:0003226","label":"Rectilinear intracellular accumulation of autofluorescent lipopigment storage material","primary":false},{"hpoId":"HP:0001250","label":"Seizure","primary":false},{"hpoId":"HP:0003657","label":"Vascular granular osmiophilic material deposition","primary":false},{"hpoId":"HP:0002367","label":"Visual hallucination","primary":false}],"ledeHtml":"CLN4 disease is a condition that primarily affects the nervous system, causing problems with movement and intellectual function that worsen over time. The signs and symptoms of CLN4 disease typically appear around age 30, but they can develop anytime between adolescence and late adulthood.","mondoId":"MONDO:0008083","node":{"canonicalSlug":"ceroid-lipofuscinosis-neuronal-4-kufs-type","comparisons":[{"documentSha256":"feab7132c1e6efa19316faa9c5b975a6a6317da700f12b5b4c059a18eda6d069","key":"legacy-cln","kind":"legacy","label":"CLN / Batten disease","memberIds":["MONDO:0008083","MONDO:0008767","MONDO:0008768","MONDO:0008769","MONDO:0009744","MONDO:0009745","MONDO:0010830","MONDO:0011144","MONDO:0012391","MONDO:0012414","MONDO:0012588","MONDO:0012721","MONDO:0013866","MONDO:0014147","MONDO:0016295"],"mondoId":"MONDO:0016295","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/cln.feab7132c1e6efa19316faa9c5b975a6a6317da700f12b5b4c059a18eda6d069.json"},{"documentSha256":"df7e5010cb40de30aba1b0d10ff00b9c8a49865234f6a0ea186c9a1493e9aae3","key":"expanded-cln","kind":"expanded","label":"CLN / Batten disease","memberIds":["MONDO:0008083","MONDO:0008767","MONDO:0008768","MONDO:0008769","MONDO:0009744","MONDO:0009745","MONDO:0010830","MONDO:0011144","MONDO:0012188","MONDO:0012391","MONDO:0012414","MONDO:0012588","MONDO:0012721","MONDO:0013866","MONDO:0014147","MONDO:0016295","MONDO:0017809","MONDO:0019260","MONDO:0019261","MONDO:0019262","MONDO:0030947","MONDO:0850001"],"mondoId":"MONDO:0016295","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/node-comparison-df7e5010cb40de30aba1.df7e5010cb40de30aba1b0d10ff00b9c8a49865234f6a0ea186c9a1493e9aae3.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":["Mutations in the DNAJC5 gene cause CLN4 disease. The DNAJC5 gene provides instructions for making a protein called cysteine string protein alpha (CSPα). This protein is found in the brain, where it plays a role in the transmission of nerve impulses, helping nerve cells communicate with each other. Specifically, CSPα is involved in recycling certain proteins that are involved in nerve impulse transmission by refolding misshapen proteins so that they can be used in additional transmissions.","DNAJC5 gene mutations lead to the production of an altered CSPα protein. The altered protein cannot perform its function, which reduces protein recycling, causing a shortage (deficiency) of functional proteins needed for impulse transmission. Without normal communication between nerve cells, neurological functions are impaired, contributing to the features of CLN4 disease.","CLN4 disease, like other NCLs, is characterized by the accumulation of proteins and other substances in lysosomes, which are compartments in the cell that digest and recycle materials. These accumulations occur in cells throughout the body; however, nerve cells seem to be particularly vulnerable to their effects. The accumulations can cause cell damage leading to cell death. The progressive death of nerve cells in the brain and other tissues contributes to the decline of neurological function in CLN4 disease. However, it is unclear how mutations in the DNAJC5 gene are involved in the buildup of substances in lysosomes."],"causesUrl":"https://medlineplus.gov/genetics/condition/cln4-disease/#causes","contentForm":"summary","matchMethod":"reviewed-binding","name":"CLN4 disease","paragraphs":["CLN4 disease is a condition that primarily affects the nervous system, causing problems with movement and intellectual function that worsen over time. The signs and symptoms of CLN4 disease typically appear around age 30, but they can develop anytime between adolescence and late adulthood.","People with CLN4 disease often develop seizures and uncontrollable muscle jerks (myoclonic epilepsy), a decline in intellectual function (dementia), problems with coordination and balance (ataxia), tremors or other involuntary movements (motor tics), and speech difficulties (dysarthria). The signs and symptoms of CLN4 disease worsen over time, and affected individuals usually survive about 15 years after the disorder begins.","CLN4 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. (The adult forms of NCLs, which includes CLN4 disease, are sometimes known as Kufs disease.) All the NCLs affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation \"CLN,\" meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype."],"reviewed":"2017-01","scope":"exact","scopeNote":"","source":"MedlinePlus","sourceRelease":"2026-10-01","upstream":"MedlinePlus Genetics","url":"https://medlineplus.gov/genetics/condition/cln4-disease"},"ownColumnKeys":["population-e10385c957f361faffe8"],"publication":"published","relationships":[{"kind":"parent","label":"adult neuronal ceroid lipofuscinosis","mondoId":"MONDO:0019260","slug":"adult-neuronal-ceroid-lipofuscinosis"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"native-cross-reference-does-not-establish-scope","source":"MedlinePlus","url":"https://medlineplus.gov/genetics/condition/cln4-disease"}],"translation":"pending","articles":[{"articleId":"rarediseases.info.nih.gov/diseases/1222","pageMondoId":"MONDO:0008083","source":"GARD","name":"Ceroid lipofuscinosis, neuronal, 4 (Kufs type)","url":"https://rarediseases.info.nih.gov/diseases/1222","relationToPage":"same-condition","coveredMondoIds":["MONDO:0008083"],"status":"validated-exact-source","presentation":"additional-reference","evidence":["existing-offline-scope-validator","automatic-identity-and-attribution"],"reviewed":null,"sourceRelease":"2026-10-25T03:38:27Z","upstream":"GARD:0001222","rawAttribution":"MONDO:0008083","independentCorroborationEstablished":false}]},"records":[{"frequencyKind":"reported","key":"084c236607bba227797c1844cef956fc4a7394a4aee5f709fc3bf61776bd99a9","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003205","is_excluded":false,"label":"Curvilinear intracellular accumulation of autofluorescent lipopigment storage material","onset_id":null,"reference":"OMIM:162350","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"0e398dfeb71117633ac390cdf24bf381712688a97fd9d6137836b2fd2d658d4e","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0002069","is_excluded":false,"label":"Bilateral tonic-clonic seizure","onset_id":"HP:0011462","reference":"PMID:21820099","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"2f2c4dff1498b9881816ae90dfe0a8b7d30b88b293a7c37b7fd9d54df44013ba","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0032794","is_excluded":false,"label":"Myoclonic seizure","onset_id":"HP:0011462","reference":"PMID:21820099","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"40c65404fd20f6274b6ebfad7651c2b7b0465d094b012943adf6d5ab37dfcc1d","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001300","is_excluded":false,"label":"Parkinsonism","onset_id":null,"reference":"OMIM:162350","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"4b0e87dd303a42317cae57f63aaef2c6bff3f4bba3c8d9b294bd872802a278bf","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0000716","is_excluded":false,"label":"Depression","onset_id":null,"reference":"PMID:21820099","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"5ef8fd4633e0672fcdf93f3be65e761888d0c5cfb15b40a50c8a118a2a0bc374","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001251","is_excluded":false,"label":"Ataxia","onset_id":null,"reference":"OMIM:162350","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"63aa04dcdbd5940c65cfa6ac59b50cb0550f3716c70b9ebabaffced5825b6ee5","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001336","is_excluded":false,"label":"Myoclonus","onset_id":null,"reference":"OMIM:162350","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"7111795ce66f6eb98ec211996d5116e6ff83e7507f19e344e793513044af079b","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0002367","is_excluded":false,"label":"Visual hallucination","onset_id":null,"reference":"OMIM:162350","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"82e47ed85797203888ca365222a9acffe00f8fd5baad5c7f1186e59ba71cde1e","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001317","is_excluded":false,"label":"Abnormal cerebellum morphology","onset_id":null,"reference":"OMIM:162350","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"8a18de3696c522566e6bfdb3d1668d3cfe6546ae6bb23b4379231e40cfc7bc6f","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0008765","is_excluded":false,"label":"Auditory hallucination","onset_id":null,"reference":"OMIM:162350","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"8f594580ea777b2403e502629f354d4343df6efd6011fd40a42c62549b91dcfa","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003208","is_excluded":false,"label":"Fingerprint intracellular accumulation of autofluorescent lipopigment storage material","onset_id":null,"reference":"OMIM:162350","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"9936b8282b19d66636d0a823e74439313806e61960f320725dde99ad979d1542","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0003657","is_excluded":false,"label":"Vascular granular osmiophilic material deposition","onset_id":null,"reference":"PMID:21820099","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"ab85586d56b4ef67f9553a21315dd00d33a6c06b5d967e9a85db2642956ff356","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0000726","is_excluded":false,"label":"Dementia","onset_id":null,"reference":"PMID:21820099","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"bab6e4ecbc77258986369e47c1b8c0c33d3834a696bc04fa952476b727b8526e","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002074","is_excluded":false,"label":"Increased neuronal autofluorescent lipopigment","onset_id":null,"reference":"OMIM:162350","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"e3f5791da630ebe0712e1778f68fa48c8dd5cc195d1ecfc9ad9afe88d220fc67","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001250","is_excluded":false,"label":"Seizure","onset_id":null,"reference":"OMIM:162350","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"ebc0184364a2b557b59d3862155df896c281ca7c70b68d4169269ec14e857210","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002071","is_excluded":false,"label":"Abnormality of extrapyramidal motor function","onset_id":null,"reference":"OMIM:162350","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"fc634fce0cdc4b94182201a6d5eb928e2c0c218aec96b6aa387d14711e90847e","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:162350","disease_name":"Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003226","is_excluded":false,"label":"Rectilinear intracellular accumulation of autofluorescent lipopigment storage material","onset_id":null,"reference":"OMIM:162350","source_release":"2026-06-23"},"sourceGroups":["omim"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln4-disease\" rel=\"noreferrer\">MedlinePlus</a></p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/1222\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0008083\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>reviewed-binding</dd><dt>Upstream attribution</dt><dd>MedlinePlus Genetics</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>CLN4 disease is a condition that primarily affects the nervous system, causing problems with movement and intellectual function that worsen over time. The signs and symptoms of CLN4 disease typically appear around age 30, but they can develop anytime between adolescence and late adulthood.</p><p>People with CLN4 disease often develop seizures and uncontrollable muscle jerks (myoclonic epilepsy), a decline in intellectual function (dementia), problems with coordination and balance (ataxia), tremors or other involuntary movements (motor tics), and speech difficulties (dysarthria). The signs and symptoms of CLN4 disease worsen over time, and affected individuals usually survive about 15 years after the disorder begins.</p><p>CLN4 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. (The adult forms of NCLs, which includes CLN4 disease, are sometimes known as Kufs disease.) All the NCLs affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation &quot;CLN,&quot; meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype.</p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln4-disease\" rel=\"noreferrer\">MedlinePlus</a></p>","key":"overview","title":"Overview"},{"bodyHtml":"<p>Mutations in the DNAJC5 gene cause CLN4 disease. The DNAJC5 gene provides instructions for making a protein called cysteine string protein alpha (CSPα). This protein is found in the brain, where it plays a role in the transmission of nerve impulses, helping nerve cells communicate with each other. Specifically, CSPα is involved in recycling certain proteins that are involved in nerve impulse transmission by refolding misshapen proteins so that they can be used in additional transmissions.</p><p>DNAJC5 gene mutations lead to the production of an altered CSPα protein. The altered protein cannot perform its function, which reduces protein recycling, causing a shortage (deficiency) of functional proteins needed for impulse transmission. Without normal communication between nerve cells, neurological functions are impaired, contributing to the features of CLN4 disease.</p><p>CLN4 disease, like other NCLs, is characterized by the accumulation of proteins and other substances in lysosomes, which are compartments in the cell that digest and recycle materials. These accumulations occur in cells throughout the body; however, nerve cells seem to be particularly vulnerable to their effects. The accumulations can cause cell damage leading to cell death. The progressive death of nerve cells in the brain and other tissues contributes to the decline of neurological function in CLN4 disease. However, it is unclear how mutations in the DNAJC5 gene are involved in the buildup of substances in lysosomes.</p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln4-disease/#causes\" rel=\"noreferrer\">MedlinePlus</a></p>","key":"causes","title":"Causes"}],"sharedSources":[],"slug":"ceroid-lipofuscinosis-neuronal-4-kufs-type","sourceDocuments":[{"name":"MedlinePlus: CLN4 disease","reviewed":"2017-01","source_release":"2026-10-01","url":"https://medlineplus.gov/genetics/condition/cln4-disease"},{"name":"GARD: Ceroid lipofuscinosis, neuronal, 4 (Kufs type)","reviewed":null,"source_release":"2026-10-25T03:38:27Z","url":"https://rarediseases.info.nih.gov/diseases/1222"},{"name":"MONDO: ceroid lipofuscinosis, neuronal, 4 (Kufs type)","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0008083"}],"sourceNote":"","synonyms":["adult neuronal ceroid lipofuscinosis 4B","autosomal dominant Kufs disease","ceroid lipofuscinosis, neuronal, 4 (Kufs type)","ceroid lipofuscinosis, neuronal, 4 (Kufs type), autosomal dominant","ceroid lipofuscinosis, neuronal, 4B, autosomal dominant","CLN4","CLN4B","Kuf's disease type B","Kuf's disease, autosomal dominant","neuronal ceroid lipofuscinosis type 4B","neuronal ceroid lipofuscinosis, parry type"],"takeawayHtml":"","title":"ceroid lipofuscinosis, neuronal, 4 (Kufs type)"},"schemaVersion":1}
